StockNews.AI
AVDL
StockNews.AI
176 days

Avadel Pharmaceuticals Appoints Kevin Springman as Vice President of Sales

1. Kevin Springman joins as VP of Sales, boosting AVDL's commercial strategy. His role is critical for LUMRYZ expansion. 2. New appointment targets enhanced sales execution for LUMRYZ, the FDA-approved narcolepsy treatment. This move aims to unlock a billion-dollar market. 3. Springman brings over 25 years of sales and rare disease expertise. His leadership supports rapid growth in competitive environments. 4. Avadel continues its strategy with an active search for a new commercial leader. The decision underscores its commitment to market leadership.

13m saved
Insight
Article

FAQ

Why Bullish?

The appointment of an experienced executive like Springman is likely to accelerate LUMRYZ's market penetration, similar to past pharma leadership changes that drove share price gains. More effective sales strategies have historically boosted investor confidence in emerging biopharma products.

How important is it?

This executive hiring is directly aligned with AVDL's strategic push to expand LUMRYZ's market share and drive growth. The move is significant enough to alter near-term sales execution and investor sentiment, making it highly relevant.

Why Short Term?

Leadership changes typically deliver near-term operational improvements and market sentiment shifts, particularly during key product launches like LUMRYZ.

Related Companies

AVDL
DUBLIN, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced that Kevin Springman has joined the company as Vice President of Sales. Mr. Springman is an accomplished executive with experience leading sales, market access and commercial teams, and executing rare disease drug launches in competitive markets. "We’re delighted to welcome Kevin to Avadel – he’s a great addition to our team with the deep experience to help us drive success at this important time," said Greg Divis, Chief Executive Officer of Avadel Pharmaceuticals. "Kevin’s expertise and proven track record in building and leading specialized sales teams will be invaluable as we continue building momentum behind the launch of LUMRYZ, our FDA-approved innovative treatment for narcolepsy.” Avadel is executing a comprehensive commercial strategy to increase demand for LUMRYZ™, with the goal of enhancing the experience for both patients and providers and unlocking the billion-dollar market potential of LUMRYZ. Avadel’s commercial launch in narcolepsy and ongoing progress in its investigational, Phase 3 trial in idiopathic hypersomnia (IH) positions the company to solidify its leadership in the sleep space and transform care for patients with sleep disorders. Mr. Springman brings more than 25 years of sales, marketing and market access leadership to Avadel. He started his sales career at AstraZeneca, where he spent 22 years, rising to become Franchise Head, Infectious Disease. Later, Mr. Springman was Vice President, Head of Immunology & Rare Disease Franchises at Sobi – North America. After that, he was President of the Americas at Albireo Pharma, where he helped build the company’s commercial infrastructure and led a specialized sales and market access team. Most recently, Mr. Springman was an independent consultant to rare disease and specialty pharma companies. “I’m excited to join Avadel at such a pivotal moment in the launch of LUMRYZ,” said Mr. Springman. “Avadel has an exceptional opportunity with LUMRYZ, built on a strong foundation in sleep medicine. I look forward to optimizing our sales strategy and execution to drive LUMRYZ’s continued growth and market leadership while improving patients’ lives.” Avadel is intent on further strengthening its executive team and is progressing its search for a new leader of its commercial organization. About LUMRYZ™ (sodium oxybate) for extended-release oral suspension  LUMRYZ, is an extended-release sodium oxybate medication approved by the FDA on May 1, 2023, as the first and only once-at-bedtime treatment for cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy.   The FDA approval of LUMRYZ was supported by results from REST-ON, a randomized, double-blind, placebo-controlled, pivotal Phase 3 trial in adults with narcolepsy. LUMRYZ demonstrated statistically significant and clinically meaningful improvements in the three co-primary endpoints: EDS, clinicians’ overall assessment of patients’ functioning (CGI-I) and cataplexy attacks, for all three evaluated doses when compared to placebo.   With its approval, the FDA also granted seven years of Orphan Drug Exclusivity to LUMRYZ for the treatment of cataplexy or EDS in adults with narcolepsy due to a finding of clinical superiority of LUMRYZ relative to currently available oxybate treatments. In particular, the FDA found that LUMRYZ makes a major contribution to patient care over currently available, twice-nightly oxybate products by providing a once-nightly dosing regimen that avoids nocturnal arousal to take a second dose. About Avadel Pharmaceuticals plc Avadel Pharmaceuticals plc (Nasdaq: AVDL) is a biopharmaceutical company focused on transforming medicines to transform lives. Our approach includes applying innovative solutions to the development of medications that address the challenges patients face with current treatment options. Avadel’s commercial product, LUMRYZ™, was approved by the U.S. Food & Drug Administration (FDA) as the first and only once-at-bedtime oxybate for the treatment of cataplexy or EDS in patients 7 years of age and older with narcolepsy. For more information, please visit www.avadel.com. IMPORTANT SAFETY INFORMATION WARNING: Taking LUMRYZ™ (sodium oxybate) with other central nervous system (CNS) depressants, such as medicines used to make you fall asleep, including opioid analgesics, benzodiazepines, sedating antidepressants, antipsychotics, sedating anti-epileptic medicines, general anesthetics, muscle relaxants, alcohol or street drugs, may cause serious medical problems, including trouble breathing (respiratory depression), low blood pressure (hypotension), changes in alertness (drowsiness), fainting (syncope) and death.The active ingredient of LUMRYZ (sodium oxybate) is a form of gamma hydroxybutyrate (GHB), a controlled substance. Abuse or misuse of illegal GHB alone or with other CNS depressants (drugs that cause changes in alertness or consciousness) have caused serious side effects. These effects include seizures, trouble breathing (respiratory depression), changes in alertness (drowsiness), coma and death. Call your doctor right away if you have any of these serious side effects.Because of these risks, LUMRYZ is available only by prescription and filled through certified pharmacies in the LUMRYZ REMS. You must be enrolled in the LUMRYZ REMS to receive LUMRYZ. Further information is available at www.LUMRYZREMS.com or by calling 1-877-453-1029.INDICATIONSLUMRYZ (sodium oxybate) for extended-release oral suspension is a prescription medicine used to treat the following symptoms in patients 7 years of age and older with narcolepsy: sudden onset of weak or paralyzed muscles (cataplexy)excessive daytime sleepiness (EDS) Do not take LUMRYZ if you take or your child takes other sleep medicines or sedatives (medicines that cause sleepiness), drink alcohol or have a rare problem called succinic semialdehyde dehydrogenase deficiency. Keep LUMRYZ in a safe place to prevent abuse and misuse. Selling or giving away LUMRYZ may harm others and is against the law. Tell your doctor if you or your child have ever abused or been dependent on alcohol, prescription medicines or street drugs. Anyone who takes LUMRYZ should not do anything that requires them to be fully awake or is dangerous, including driving a car, using heavy machinery or flying an airplane, for at least six (6) hours after taking LUMRYZ. Those activities should not be done until you know how LUMRYZ affects you. Falling asleep quickly, including while standing or while getting up from the bed, has led to falls with injuries that have required some people to be hospitalized. LUMRYZ can cause serious side effects, including the following: Breathing problems, including slower breathing, trouble breathing and/or short periods of not breathing while sleeping (e.g., sleep apnea). People who already have breathing or lung problems have a higher chance of having breathing problems when they take LUMRYZ.Mental health problems, including confusion, seeing or hearing things that are not real (hallucinations), unusual or disturbing thoughts (abnormal thinking), feeling anxious or upset, depression, thoughts of killing yourself or trying to kill yourself, increased tiredness, feelings of guilt or worthlessness and difficulty concentrating. Tell your doctor if you or your child have or had depression or have tried to harm yourself. Call your doctor right away if you or your child have symptoms of mental health problems or a change in weight or appetite.Sleepwalking. Sleepwalking can cause injuries. Call your doctor if you or your child start sleepwalking. Tell your doctor if you or your child are on a salt-restricted diet or have high blood pressure, heart failure or kidney problems. LUMRYZ contains a lot of sodium (salt) and may not be right for you. The most common side effects of LUMRYZ in adults include nausea, dizziness, bedwetting, headache and vomiting. Your side effects may increase when you take higher doses of LUMRYZ. The most common side effects in children include nausea, bedwetting, vomiting, headache, decreased weight, decreased appetite, dizziness, and sleepwalking. LUMRYZ can cause physical dependence and craving for the medicine when it is not taken as directed. These are not all the possible side effects of LUMRYZ. For more information, ask your doctor or pharmacist. Call your doctor for medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088. Please see full Prescribing Information, including BOXED Warning. Cautionary Disclosure Regarding Forward-Looking StatementsThis press release includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements relate to our future expectations, beliefs, plans, strategies, objectives, results, conditions, financial performance, prospects or other events. Such forward-looking statements include, but are not limited to, statements regarding our plans and strategies for LUMRYZ; expectations regarding the potential market opportunity for LUMRYZ; expectations regarding Avadel’s ability to seek and obtain FDA approval for, as well as, commercially launch LUMRYZ for indications beyond narcolepsy; and expectations regarding the anticipated contribution of new employees to our operations and progress. In some cases, forward-looking statements can be identified by the use of words such as “will,” “may,” “could,” “believe,” “expect,” “look forward,” “on track,” “guidance,” “anticipate,” “estimate,” “project,” “next steps” and similar expressions and the negatives thereof (if applicable). The Company’s forward-looking statements are based on estimates and assumptions that are made within the bounds of our knowledge of our business and operations and that we consider reasonable. However, the Company’s business and operations are subject to significant risks, and, as a result, there can be no assurance that actual results and the results of the company’s business and operations will not differ materially from the results contemplated in such forward-looking statements. Factors that could cause actual results to differ from expectations in the Company’s forward-looking statements include final audit adjustments and other developments that may arise that would cause the Company’s expectations with respect to the estimate of revenue for the fourth quarter of 2024 and cash as of December 31, 2024 to differ, perhaps materially, from the financial results that will be reflected in the Company’s audited consolidated financial statements for the fiscal year ended December 31, 2024, and the risks and uncertainties described in the “Risk Factors” section of Part I, Item 1A of the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, which was filed with the Securities and Exchange Commission (SEC) on February 29, 2024, and subsequent SEC filings. Forward-looking statements speak only as of the date they are made and are not guarantees of future performance. Accordingly, you should not place undue reliance on forward-looking statements. The Company does not undertake any obligation to publicly update or revise our forward-looking statements, except as required by law. Investor Contact:Austin MurtaghPrecision AQAustin.Murtagh@precisionaq.com(212) 698-8696 Media Contact:Lesley StanleyReal Chemistrylestanley@realchemistry.com(609) 273-3162

Related News